Navigation Links
Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients

ally to assess the safety of ISIS 301012 in HoFH and in combination with high-dose concurrent lipid-lowering therapies, the protocol initially called for five weeks of dosing. Based on a strong safety profile at five weeks with doses through 200 mg/week, the study was amended to include a cohort of patients dosed at 300 mg/week for three months, and it is that cohort for which Isis is updating the interim data presented at the ACC. Because HoFH is an extremely rare condition affecting one person per million, clinical trials in this disease are generally quite small.

The study included three HoFH patients with very high incoming LDL-cholesterol levels despite being treated with maximally-tolerated lipid-lowering therapies. Throughout the study, all patients remained on their other lipid-lowering drugs at constant doses. With this update, all patients completed 12 weeks of study treatment and reached the primary endpoint for analysis at Day 99, 14 days after receiving their last dose of ISIS 301012. The patients continue in follow-up. The data are summarized in tabular form below.



    Table 1: ISIS 301012 in HoFH, Summary of Results

    Lipid values are presented in mg/dL and % change from baseline.


                  Patient 1         Patient 2          Patient 3


                                      80 mg

                                   atorvastatin +

    Concurrent                   10 mg ezetimibe +

    Lipid-                            3.75 g              40 mg

    lowering        80 mg          colesevelam +      rosuvastatin +

    Therapies    atorvastatin       1 g niacin        10 mg ezetimibe


    Age

     (years)        23                  48                  32


    Lipids: Base-   Day    %     Base- Day    %     Base-  Day    %

            line    99   change  line  99   change  line   99   change

    ApoB     369    171   -54%   180   103   -43%   283    156   -45%

    LDL-C    651    318   -51%   197    99   -50%   4
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:9/30/2014)... 2014 MiMedx Group, Inc. (NASDAQ: ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of ... Chief Scientific Officer, will present at the Stem Cell ... Tuesday, October 7, 2014, at 5:00PM Pacific Daylight Time. ...
(Date:9/30/2014)... 30, 2014 STUDY OBJECTIVES The ... to provide an overview of the current and ... drugs/therapeutics. The key objective is to present a ... as an important tool in the treatment of ... future strategies within the protein therapeutics market, which ...
(Date:9/30/2014)... -- Decision Resources Group finds that the markets for peripheral ... Russia , India ... see robust expansion as these economies expand and as ... revenues will be somewhat impeded by poor distribution of ... and demand for low-cost products, the market will ultimately ...
Breaking Medicine Technology:MiMedx to Present at the Stem Cell Meeting on the Mesa 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3
... Inc. (NYSE: BMR ) announced today the ... (NASDAQ: DEPO ) at its Pacific Research ... company, leased approximately 60,000 square feet of space at ... Research Center campus. Commenting on their relocation ...
... Med-Tek a developer of Healthcare Technology Networks ("HTN") designed ... constituents today announces the launch of its proprietary Opioid ... United States Bone & Joint Decade ... individuals suffering from musculoskeletal disease filled 1.6 billion prescriptions. ...
Cached Medicine Technology:New 60,000 Square Foot Lease at the Pacific Research Center Signed by Biomed Realty and Depomed 2New 60,000 Square Foot Lease at the Pacific Research Center Signed by Biomed Realty and Depomed 3Med-Tek Launches the First Evidenced Based Opioid Management Program (OMP) 2
(Date:10/1/2014)... 1, 2014) Despite a policy focus on ... disabilities, this vulnerable population continues to have significant ... The Journal of the American Dental Association , ... Tufts University School of Dental Medicine report on ... at-home oral care provided by caregivers to adults ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog post ... for vulnerable family members. , Life insurance plans provide ... the family should always carry a life insurance policy ... rest of the family. , Clients can choose ... from temporary coverage or from a permanent policy. No ...
(Date:10/1/2014)... Oregon (PRWEB) October 01, 2014 Phoseon ... solutions , continues to expand the business worldwide. This ... along with additional capacity for manufacturing efforts. The company ... the last five years and expects this growth to ... LED curing technology gains worldwide adoption. , “We ...
(Date:10/1/2014)... A new genetic finding from Duke Medicine suggests that ... depression might also be hard-wired to gain weight when ... disease. , An estimated 13 percent of people, all ... and knowing this could help them reduce heart disease ... and stress management. , "Genetic susceptibility, psychosocial stress and ...
(Date:10/1/2014)... 2014 Diet Doc understands that many of ... weight and their dieting attempts could be easily sabotaged by ... hormone diet treatments into their programs as a way ... fast and effective weight loss results, it also allows patients ... to maintain their weight for the future. , Earlier versions ...
Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4
... are reluctant to go in for research collaborations though the ... than in many Southeast Asian nations. ... a great reluctance towards online education in this country, London ... ,"In India, the emphasis is still on the teacher ...
... the incidence of asthma increases by 50 percent,// as ... meta-analysis of seven studies on severe asthma involving 333,102 ... 2007 of the American Journal of Respiratory and Critical ... ,E. Rand Sutherland, M.D., M.P.H., of the ...
... more easily when they figure out the words' meaning for ... ,Meredith Brinster, an undergraduate student in the John ... found that learning words by inference is more powerful for ... ,"One of the things that is particularly exciting about the ...
... health insurance through the state children’s health insurance ... racial disparities are eliminated and more preventive care ... more counseling from their health care providers about ... issues that impact their long-term health. ...
... continuity disturbance impairs endogenous pain-inhibitory function and increases spontaneous ... of sleep disturbance in chronic pain, according to a ... journal SLEEP., ,The study, conducted by Michael T. ... on 32 healthy females, who were studied polysomnographically for ...
... Exposure to a type of bacteria found in soil boosts ... people who are depressed and prone to infection, says a ... Bristol University treated lung cancer patients with the bacteria, named ... life, reported the online edition of BBC News. ...
Cached Medicine News:Health News:LondonMet Keen on Widening Research Collaborations With India 2Health News:LondonMet Keen on Widening Research Collaborations With India 3Health News:Asthma Incidence Shows a 50 Percent Increase in Fat People 2Health News:Learning Words by Inference More Powerful for Toddlers 2Health News:Teens Get Needed Access to Care With State Health Insurance 2Health News:Teens Get Needed Access to Care With State Health Insurance 3Health News:New Study in SLEEP Finds That Sleep Disturbance Increases Spontaneous Pain in Women 2
... spill-proof design and effective output, even when ... medical nebulizers are free-standing for easy preparation., ... available., ,All Portex® medication nebulizer products ... feature consistently fine misting and the efficient ...
... Portex® medication nebulizers offer a spill-proof ... up to a 45° angle. All medical ... ,A wide variety of configurations are available., ... latex-free. , ,Portex® medication nebulizers feature ...
... inhalers., ,ACE ensures prompt, effective delivery ... versatile design allows it to be used ... an endotracheal airway or resuscitation bag and ... be used in conjunction with an incentive ...
... can be held at angles up to 45° ... in spill column, finger grooves for a non-slip ... 7 feet of regular oxygen tubing. The ... size and sustain optimum mist concentration at every ...
Medicine Products: